ROIVANT SCIENCES LTD. Stockholders' Equity Attributable to Noncontrolling Interest
ROIVANT SCIENCES LTD. (ROIV) had Stockholders' Equity Attributable to Noncontrolling Interest of $690.60 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:MinorityInterest · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Noncontrolling Interest $690.60M.
- 2026-03-31: Stockholders' Equity Attributable to Noncontrolling Interest $765.04M.
- 2025-12-31: Stockholders' Equity Attributable to Noncontrolling Interest $704.97M.
- 2025-09-30: Stockholders' Equity Attributable to Noncontrolling Interest $443.13M.
| Period end | Stockholders' Equity Attributable to Noncontrolling Interest |
|---|---|
| 2026-06-30 | $690.60M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $765.04M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $704.97M 10-Q · filed 2026-02-06 |
| 2025-09-30 | $443.13M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $470.27M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $499.59M 10-K · filed 2026-05-20 |
| 2024-12-31 | $346.50M 10-Q · filed 2025-02-10 |
| 2024-09-30 | $427.09M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $459.98M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $479.95M 10-K · filed 2025-05-29 |
| 2023-12-31 | $494.82M 10-Q · filed 2024-02-13 |
| 2023-09-30 | $377.10M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $423.41M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $449.82M 10-K · filed 2024-05-30 |
| 2022-12-31 | $471.62M 10-Q · filed 2023-02-13 |
| 2022-09-30 | $353.55M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $371.28M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $382.00M 10-K · filed 2023-06-28 |
| 2021-12-31 | $381.54M 10-Q · filed 2022-02-14 |
| 2021-09-30 | $390.39M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $234.22M 10-Q · filed 2021-09-21 |
| 2021-03-31 | $241.73M 10-K · filed 2022-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |